GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PYC Therapeutics PYC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

1.99

+5.85%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−A$43.3m

FY2017FY2026

Free cash flow

−A$45.1m

FY2017FY2026

Shareholders' equity

A$693.3m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue—A$23.5mA$22.1mA$15.8mA$16.0mA$3.1mA$2.4mA$250A$48,460A$2.8m
Gross profit−A$1.2mA$23.5mA$22.1mA$14.9mA$15.2mA$2.5mA$1.8m−A$130,556−A$32,838−A$1.9m
Research and developmentA$74.0mA$70.1mA$56.4mA$35.1mA$24.0mA$14.0mA$5.9mA$4.5mA$7.0mA$4.7m
Operating income−A$82.7m−A$53.6m−A$38.9m−A$39.2m−A$30.2m−A$21.8m−A$9.7m−A$7.1m−A$9.8m−A$4.3m
Net income−A$43.3m−A$50.3m−A$37.7m−A$22.8m−A$13.9m−A$17.8m−A$6.8m−A$4.1m−A$7.4m−A$2.0m
Diluted earnings per share-0.06-0.08-0.01-0.01-0.00-0.01-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsA$708.5mA$183.3mA$91.2mA$37.2mA$45.4mA$57.9mA$31.5mA$6.7mA$3.4mA$10.3m
Cash and short-term investmentsA$447.6mA$153.1mA$66.9mA$15.6mA$29.1mA$51.5mA$25.4mA$6.2mA$3.1mA$9.9m
Total liabilitiesA$15.2mA$13.3mA$10.2mA$8.7mA$5.1mA$4.0mA$1.4mA$401,874A$1.8mA$1.5m
DebtA$624,988A$1.0mA$1.1mA$315,487A$943,769A$730,354A$798,147A$798,145——
Shareholders' equityA$693.3mA$169.6mA$80.5mA$27.7mA$39.4mA$53.0mA$28.5mA$6.3mA$1.6mA$8.9m
Shares outstanding733m597m3,936m3,777m3,219m3,219m3,209m2,953m2,364m2,124m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−A$44.5m−A$51.6m−A$38.6m−A$24.4m−A$21.8m−A$11.8m−A$5.7m−A$5.1m−A$6.7m−A$1.9m
Capital spending−A$531,387−A$975,397−A$307,044−A$491,116−A$386,912−A$591,030−A$106,097−A$457,539−A$210,577−A$4,535
Free cash flow−A$45.1m−A$52.5m−A$38.9m−A$24.9m−A$22.2m−A$12.4m−A$5.9m−A$5.6m−A$6.9m−A$1.9m
Dividends paid———−A$10.5m—−A$36.3m−A$23.5m———

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023
Revenue—A$11.0mA$11.7mA$11.8mA$13.2mA$8.9mA$12.3mA$6.2m
Gross profit−A$901,196−A$302,802A$11.7mA$11.8mA$13.2mA$8.6mA$12.2mA$6.2m
Operating income−A$49.0m−A$33.6m−A$26.9m−A$26.7m−A$23.4m−A$15.4m−A$18.8m−A$3.2m
Net income−A$20.5m−A$22.8m−A$24.7m−A$25.6m−A$22.6m−A$15.1m−A$6.6m−A$3.3m
Diluted earnings per share-0.03-0.04-0.04-0.01-0.01-0.00-0.00-0.00
Cash from operations−A$13.0m−A$31.0m−A$34.0m−A$17.0m−A$31.0m−A$6.0m−A$12.0m−A$6.0m
Total assetsA$708.5mA$159.1mA$183.3mA$68.2mA$91.2mA$39.8mA$37.2mA$37.2m
Cash and short-term investmentsA$447.6mA$120.7mA$153.1mA$49.3mA$66.9mA$25.4mA$15.6mA$15.6m
DebtA$356,518A$827,083A$1.0mA$1.2mA$1.1mA$868,598A$315,486—
Shareholders' equityA$693.3mA$147.2mA$169.6mA$55.4mA$80.5mA$29.9mA$27.7mA$21.9m

Financial ratios

Data as of 3 Nov 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin—100.0%100.0%94.4%94.8%79.8%77.2%
Operating margin—-228.3%-252.1%-247.6%-188.5%-704.6%-393.7%
Net margin—-214.1%-171.0%-144.2%-86.4%-577.9%-284.8%
Return on equity-6.3%-29.7%-46.9%-82.1%-35.2%-33.5%—
Return on assets-6.1%-27.4%-41.3%-61.3%-30.6%-30.7%—
Free cash flow yield-3.3%-4.7%-0.5%-0.4%-0.4%-0.2%—
Revenue growth—6.5%39.6%-1.5%421.8%28.3%958182.4%
Earnings growth-13.8%33.3%65.5%64.4%-22.0%160.4%—
Current ratio33.48x14.41x9.40x3.79x8.94x15.71x—
Debt to equity0.00x0.00x0.00x0.01x0.01x0.00x—
Equity ratio97.9%92.5%88.2%74.7%86.8%91.5%—
Interest coverage-2043.25x-861.87x-1130.29x-1434.16x-927.57x-557.99x—
R&D as a share of sales—298.2%255.7%222.4%149.8%455.5%245.3%
Buybacks as a share of market value-22.7%84.8%-4.2%-17.4%0.0%-0.3%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income28.3%30.5%30.1%
Net income23.9%19.5%27.0%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-32.6-19.6-137.7-180.2-158.3-241.7-685.6-440.5-86.0-420.6
Price to sales—42.1235.5259.8136.8————297.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 15 Nov 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.